Author

Oliver Gerhard Ottmann

Cardiff UniversityORCID 0000-0001-9559-1330Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Afsar Ali MianiD· 2 shared Ambrin FatimaiD· 1 shared Andreas Otto· 1 shared Carol Guy· 1 shared Caroline AlvaresiD· 1 shared Claudia ChirichesiD· 1 shared Dörte BecheriD· 1 shared Fawad Ur RehmaniD· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Afsar Ali MianORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologybioRxivPreprintNov 28, 2023

Prioritization of The Zinc finger domain within BCL11A gene by the Amelioration capability of hemoglobinopathies using CRISPR-Cas9 technology

Kainaat Mumtaz, Irfan Hussain, Fizza Iftikhar…·Afsar Ali Mian

This study uses CRISPR-Cas9 to investigate BCL11A zinc finger domains' role in gamma-globin regulation and hemoglobinopathy treatment, finding Znf4 deletion increases HbF levels.

DOI 10.1101/2023.11.28.568974

humanCRISPR screen

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 7, 2018

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated by an Oncogenic Transcription Factor in Acute Myeloid Leukemia

Nathalie Guillen, Maria Wieske, Andreas Otto…·Claudia Chiriches

This study uses subtractive interaction proteomics to identify signaling pathways activated by the t(6;9)-DEK/CAN oncogene in AML, revealing potential therapeutic targets.

DOI 10.1101/464958

humanproteomics

𝕏 PostBluesky